Nevro Corp (NVRO)

Schlusskurs vom Vortag:

$11.29

Offen:

$11.41

24-Stunden-Volumen:

299.68K

Marktkapitalisierung:

$409.00M

Einnahmen:

$425.17M

Nettoeinkommen (Verlust:

$-92.21M

KGV:

1,115.00

EPS:

0.01

Netto-Cashflow:

$-67.42M

1W Leistung:

-2.36%

1M Leistung:

-16.10%

6M Leistung:

-31.68%

1J Leistung:

-58.83%

1-Tages-Spanne:

$11.01

$11.41

52-Wochen-Spanne:

$10.27

$28.89

Nevro Corp Stock (NVRO) Company Profile

Firmenname

Nevro Corp

Sektor

Healthcare (1215)

Branche

Medical Devices (160)

Telefon

650-251-0005

Adresse

1800 Bridge Parkway, Redwood City, CA

Mitarbeiter

676

Twitter

@Nevro_HF10

Nächster Verdiensttermin

2024-05-23

Neueste SEC-Einreichungen

NVRO's Discussions on Twitter

Nevro Corp Stock (NVRO) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-01-12	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2023-12-21	Herabstufung	Canaccord Genuity	Buy → Hold
2023-07-19	Eingeleitet	Robert W. Baird	Neutral
2023-05-31	Eingeleitet	RBC Capital Mkts	Outperform
2023-05-15	Hochstufung	Oppenheimer	Perform → Outperform
2023-04-14	Eingeleitet	Mizuho	Neutral
2023-01-17	Herabstufung	Citigroup	Buy → Neutral
2023-01-06	Herabstufung	Piper Sandler	Neutral → Underweight
2022-12-20	Hochstufung	Canaccord Genuity	Hold → Buy
2022-12-12	Herabstufung	Wells Fargo	Overweight → Equal Weight
2022-10-12	Eingeleitet	Jefferies	Underperform
2022-05-05	Hochstufung	Citigroup	Neutral → Buy
2022-04-13	Fortgesetzt	Truist	Hold
2022-04-06	Eingeleitet	Wolfe Research	Underperform
2022-03-02	Fortgesetzt	BofA Securities	Underperform
2022-01-07	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2021-12-06	Hochstufung	Wells Fargo	Equal Weight → Overweight
2021-11-09	Herabstufung	Truist	Buy → Hold
2021-08-05	Herabstufung	Canaccord Genuity	Buy → Hold
2021-08-05	Herabstufung	Citigroup	Buy → Neutral
2021-08-05	Herabstufung	Piper Sandler	Overweight → Neutral
2021-08-05	Herabstufung	Wells Fargo	Overweight → Equal Weight
2021-08-05	Herabstufung	William Blair	Outperform → Mkt Perform
2021-07-09	Herabstufung	Redburn	Buy → Neutral
2021-07-06	Herabstufung	Robert W. Baird	Outperform → Neutral
2021-02-02	Eingeleitet	Piper Sandler	Overweight
2020-10-23	Eingeleitet	Guggenheim	Buy
2020-09-02	Eingeleitet	Robert W. Baird	Outperform
2020-06-08	Hochstufung	UBS	Sell → Neutral
2020-03-05	Eingeleitet	Citigroup	Buy
2020-02-26	Hochstufung	Canaccord Genuity	Hold → Buy
2020-01-08	Eingeleitet	SunTrust	Buy
2020-01-06	Herabstufung	Oppenheimer	Outperform → Perform
2019-11-07	Hochstufung	Oppenheimer	Perform → Outperform
2019-10-22	Eingeleitet	Oppenheimer	Perform
2019-03-20	Hochstufung	BofA/Merrill	Neutral → Buy
2019-03-20	Hochstufung	Wells Fargo	Market Perform → Outperform
2018-11-28	Eingeleitet	UBS	Sell
2018-11-07	Herabstufung	BofA/Merrill	Buy → Neutral
2018-11-06	Herabstufung	JP Morgan	Overweight → Neutral
2018-11-06	Herabstufung	Morgan Stanley	Equal-Weight → Underweight
2018-10-19	Herabstufung	Goldman	Neutral → Sell
2018-07-02	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2018-05-08	Bestätigt	Canaccord Genuity	Buy
2018-05-08	Herabstufung	Northland Capital	Outperform → Market Perform
2018-05-08	Herabstufung	Wells Fargo	Outperform → Market Perform

Alle ansehen

Nevro Corp Aktie (NVRO) Neueste Nachrichten

Will These 5 Medical Device Stocks Beat This Earnings Season?

Zacks Investment Research

Where Nevro Stands With Analysts

Benzinga

Abbott (ABT) Expands in Canada With First Eterna SCS Use

Zacks Investment Research

Here's Why You Should Retain Nevro (NVRO) Stock for Now

Zacks Investment Research

Nevro (NVRO) Gets FDA Nod for SI Fixation Without Lateral Screw

Zacks Investment Research

Why Nevro Stock Lagged the Market on Thursday

The Motley Fool

Finanzdaten der Nevro Corp-Aktie (NVRO)

Nevro Corp (NVRO) Umsatz 2024

Nevro Corp (NVRO) Nettogewinn 2024

Nevro Corp (NVRO) Free Cashflow 2024

Nevro Corp (NVRO) Gewinn je Aktie 2024